CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease

Brain

Volumn 139, Issue 3, 2016, Pages 953-970

  Boussicault, Lydie ^a   Alves, Sandro ^b   Lamazière, Antonin ^c   Planques, Anabelle ^a,d   Heck, Nicolas ^a   Moumné, Lara ^a   Despres, Gaëtan ^c   Bolte, Susanne ^a   Hu, Amélie ^a,e   Pagès, Christiane ^a   Galvan, Laurie ^f   Piguet, Francoise ^g   Aubourg, Patrick ^b   Cartier, Nathalie ^b   Caboche, Jocelyne ^a   Betuing, Sandrine ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b DIF   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Paris Sciences et Lettres   (France)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CNRS   (France)

Author keywords

Cholesterol; CYP46A1; Huntington's disease; Neuroprotection; Striatum

Indexed keywords

CHOLESTEROL; CHOLESTEROL 24 HYDROXYLASE; CYTOCHROME P450; CYTOCHROME P450 46A1; DESMOSTEROL; HUNTINGTIN; LANOSTEROL; MESSENGER RNA; PARVOVIRUS VECTOR; POLYGLUTAMINE; POLYGLUTAMINE EXPANSION IN HUNTINGTIN; PROTEIN AGGREGATE; UNCLASSIFIED DRUG; STEROID MONOOXYGENASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BRAIN CORTEX; BRAIN LEVEL; BRAIN NERVE CELL; CELL COUNT; CELL DEATH; CELL PROTECTION; CHOLESTEROL DEGRADATION; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; EXPERIMENTAL TEST; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIMB CLASPING TEST; MOTOR DYSFUNCTION; MOUSE; MOUSE MODEL; NERVE CELL ATROPHY; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PUTAMEN; ROTAROD TEST; VIRAL GENE DELIVERY SYSTEM; WILD TYPE MOUSE; AGED; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CBA MOUSE; CELL CULTURE; ENZYMOLOGY; HUNTINGTON DISEASE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; CHOLESTEROL; CHOLESTEROL 24-HYDROXYLASE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MIDDLE AGED; STEROID HYDROXYLASES;

EID: 84964660315     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv384     Document Type: Article

References (72)

1. Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552-60.
2. Bauer PO, Goswami A, Wong HK, Okuno M, Kurosawa M, Yamada M, et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol 2010;28:256-63. doi: 10.1038/nbt.1608. Epub 2010 Feb. 28.
3. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 2006;17:1652-63.
4. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci USA 2000;97:6809-14.
5. Bjorkhem I, Lutjohann D, Breuer O, Sakinis A, Wennmalm A. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24 (S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem 1997;272:30178-84.
6. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004;24:806-15.
7. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-40.
8. Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci USA 2005;102:12218-23.
9. Chevy F, Humbert L, Wolf C. Sterol profiling of amniotic fluid: a routine method for the detection of distal cholesterol synthesis deficit. Prenat Diagn 2005;25:1000-6.
10. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127:59-69.
11. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-48.
12. del Toro D, Xifro X, Pol A, Humbert S, Saudou F, Canals JM, et al. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. J Neurochem 2010;115:153-67.
13. Deyts C, Galan-Rodriguez B, Martin E, Bouveyron N, Roze E, Charvin D, et al. Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS One 2009;4:e8287.
14. Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004;45:1375-97.
15. Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bièche I, et al. (2015) CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain 2015;13:2383-98.
16. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002;296:2238-43.
17. Dzeletovic S, Babiker A, Lund E, Diczfalusy U. Time course of oxysterol formation during in vitro oxidation of low density lipoprotein. Chem Phys Lipids 1995;78:119-28
18. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004;118:127-38.
19. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem 2003;278:50514-22.
20. Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther 2010;18:44-53.
21. Jiang Y, Lv H, Liao M, Xu X, Huang S, Tan H, et al. GRP78 counteracts cell death and protein aggregation caused by mutant huntingtin proteins. Neurosci Lett 2012;516:182-7.
22. Karasinska, JM., Hayden MR. Cholesterol metabolism in Huntington disease. Nat Rev Neurol 2011;7:561-72.
23. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of wholebody cholesterol synthesis in humans. J Lipid Res 1988;29:1149-55.
24. Korade Z, Kenworthy AK. Lipid rafts, cholesterol, and the brain. Neuropharmacology 2008;55:1265-73.
25. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 2007;16:1845-61.
26. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, et al. Plasma 24S-hydroxycholesterol and caudate MRI in premanifest and early Huntington's disease. Brain 2008;131:2851-9.
27. Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS. Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis 2013;55:37-43.
28. Leoni V, Caccia C. The impairment of cholesterol metabolism in Huntington disease. Biochim Biophys Acta 2015;1851:1095-105. doi: 10.1016/j.bbalip. 2014.12.018. Epub 2015 Jan 14.
29. Li H, Li SH, Yu ZX, Shelbourne P, Li XJ. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 2001;21:8473-81.
30. Lim L, Jackson-Lewis V, Wong LC, Shui GH, Goh AX, Kesavapany S, et al. Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease. Cell Death Differ 2012;19:416-27.
31. Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 1999;96:7238-43.
32. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 2003;278:22980-8. Epub 2003 Apr. 9.
33. Martin MG, Perga S, Trovo L, Rasola A, Holm P, Rantamaki T, et al. Cholesterol loss enhances TrkB signaling in hippocampal neurons aging in vitro. Mol Biol Cell 2008;19:2101-12.
34. Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci 2015;38:26-35.
35. Marullo M, Valenza M, Leoni V, Caccia C, Scarlatti C, De Mario A, et al. Pitfalls in the detection of cholesterol in Huntington's disease models. PLoS Curr 2012;4:e505886e9a1968.
36. Menalled L, El-Khodor BF, Patry M, Suárez-Fariñas M, Orenstein SJ, Zahasky B, et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 2009;35:319-36.
37. Moumné L, Betuing S, Caboche J. Multiple aspects of gene dysregulation in Huntington's disease. Front Neurol 2013;4:127.
38. Milnerwood AJ, Raymond LA. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci 2010;33:513-23.
39. Nieweg K, Schaller H, Pfrieger FW. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 2009;109:125-34.
40. Nunes MJ, Milagre I, Schnekenburger M, Gama MJ, Diederich M, Rodrigues E. Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of CYP46A1 gene transcription. J Neurochem 2010;113:418-31.
41. Paul BD, Sbodio JI, Xu R, Vandiver MS, Cha JY, Snowman AM, Snyder SH. Cystathionine g-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature 2014;509:96-100.
42. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014;383:1138-46. doi: 10.1016/S0140-673661939-X.
43. Pfrieger FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta 2003;1610:271-80.
44. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003;6:345-51.
45. Renner M, Choquet D, Triller A. Control of the postsynaptic membrane viscosity. J Neurosci 2009;29:2926-37.
46. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10(Suppl):S10-7.
47. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008a; 21:497-503.
48. Roze E, Betuing S, Deyts C, Marcon E, Brami-Cherrier K, Pages C, et al. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. FASEB J 2008b; 22:1083-93.
49. Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P, Overland RP, et al. Histones associated with downregulated genes are hypoacetylated in Huntington's disease models. Hum Mol Genet 2007;16:1293-306.
50. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001;60:161-72.
51. Shafaati M, Olin M, Bavner A, Pettersson H, Rozell B, Meaney S, et al. Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo. J Intern Med 2011;270:377-87.
52. Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol 2005;4:841-52.
53. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 2002;11:1953-65.
54. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM, et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007;15:481-91.
55. Spann NJ, Garmire LX, McDonald JG, Myers DS, Milne SB, Shibata N, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 2012;151:138-52.
56. Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, et al. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 2005;490:354-70.
57. Suzuki S, Kiyosue K, Hazama S, Ogura A, Kashihara M, Hara T, et al. Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse development. J Neurosci 2007;27:6417-27.
58. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83
59. Tourette C, Farina F, Vazquez-Manrique RP, Orfila AM, Voisin J, Hernandez S, et al. The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. PLoS Biol 2014;12:e1001895.
60. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, et al. Dominant phenotypes produced by the HD mutation in STHdh (Q111) striatal cells. Hum Mol Genet 2000;9:2799-809.
61. Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG et al. Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet 2006;15:3578-91.
62. Trushina E, Canaria CA, Lee DY, McMurray CT. Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo. Hum Mol Genet 2014;23:129-44.
63. Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, et al. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 2012;4:142ra97.
64. Urano Y, Ochiai S, Noguchi N. Suppression of amyloid-beta production by 24S-hydroxycholesterol via inhibition of intracellular amyloid precursor protein trafficking. FASEB J 2013;27:4305-15.
65. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005;25:9932-9.
66. Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, Singaraja RR, et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet 2007a; 16:2187-98.
67. Valenza M, Leoni V, Tarditi A, Mariotti C, Bjorkhem I, Di Donato S, et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007b; 28:133-42.
68. Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, et al. Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 2010;30:10844-50.
69. Valenza M, Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci 2011;34:474-86.
70. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-77.
71. Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, et al. Peroxisome-proliferator-activated receptor gamma coactivator 1 a contributes to dysmyelination in experimental models of Huntington's disease. J Neurosci 2011;31:9544-53.
72. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293:493-8.